Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Buhl R, Banerji D. Int J Chron Obstruct Pulmon Dis. 2012;7:729–741. On page 737 in the first paragraph of the "Safety" section, the final sentence "Serious adverse events occurred with a slightly lower frequency in the glycopyrronium treatment group (11%) compared with placebo (...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2014-03-01
|
| Серии: | International Journal of COPD |
| Online-ссылка: | http://www.dovepress.com/httpwwwdovepresscomprofile-of-glycopyrronium-forcorrigendum-a16142 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|